• Je něco špatně v tomto záznamu ?

The effect of the sphingosine-1-phosphate analogue FTY720 on atrioventricular nodal tissue

EE. Egom, P. Kruzliak, V. Rotrekl, M. Lei,

. 2015 ; 19 (7) : 1729-34. [pub] 20150413

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010347

The sphingosine-1-phosphate (S1P) receptor modulator, fingolimod (FTY720), has been used for the treatment of patients with relapsing forms of multiple sclerosis, but atrioventricular (AV) conduction block have been reported in some patients after the first dose. The underlying mechanism of this AV node conduction blockade is still not well-understood. In this study, we hypothesize that expression of this particular arrhythmia might be related to a direct effect of FTY720 on AV node rather than a parasympathetic mimetic action. We, therefore, investigated the effect of FTY720 on AV nodal, using in vitro rat model preparation, under both basal as well as ischaemia/reperfusion conditions. We first look at the expression pattern of S1P receptors on the AV node using real-time PCR. Although all three S1P receptor isoforms were expressed in AVN tissues, S1P1 receptor isoform expression level was higher than S1P2 and S1P3. The effect of 25 nM FTY720 on cycle length (CL) was subsequently studied via extracellular potentials recordings. FTY720 caused a mild to moderate prolongation in CL by an average 9% in AVN (n = 10, P < 0.05) preparations. We also show that FTY720 attenuated both ischaemia and reperfusion induced AVN rhythmic disturbance. To our knowledge, these remarkable findings have not been previously reported in the literature, and stress the importance for extensive monitoring period in certain cases, especially in patients taking concurrently AV node blocker agents.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010347
003      
CZ-PrNML
005      
20160414121410.0
007      
ta
008      
160408s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jcmm.12549 $2 doi
024    7_
$a 10.1111/jcmm.12549 $2 doi
035    __
$a (PubMed)25864579
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Egom, Emmanuel E $u Egom Clinical and Translational Research Services, Halifax, NS, Canada.
245    14
$a The effect of the sphingosine-1-phosphate analogue FTY720 on atrioventricular nodal tissue / $c EE. Egom, P. Kruzliak, V. Rotrekl, M. Lei,
520    9_
$a The sphingosine-1-phosphate (S1P) receptor modulator, fingolimod (FTY720), has been used for the treatment of patients with relapsing forms of multiple sclerosis, but atrioventricular (AV) conduction block have been reported in some patients after the first dose. The underlying mechanism of this AV node conduction blockade is still not well-understood. In this study, we hypothesize that expression of this particular arrhythmia might be related to a direct effect of FTY720 on AV node rather than a parasympathetic mimetic action. We, therefore, investigated the effect of FTY720 on AV nodal, using in vitro rat model preparation, under both basal as well as ischaemia/reperfusion conditions. We first look at the expression pattern of S1P receptors on the AV node using real-time PCR. Although all three S1P receptor isoforms were expressed in AVN tissues, S1P1 receptor isoform expression level was higher than S1P2 and S1P3. The effect of 25 nM FTY720 on cycle length (CL) was subsequently studied via extracellular potentials recordings. FTY720 caused a mild to moderate prolongation in CL by an average 9% in AVN (n = 10, P < 0.05) preparations. We also show that FTY720 attenuated both ischaemia and reperfusion induced AVN rhythmic disturbance. To our knowledge, these remarkable findings have not been previously reported in the literature, and stress the importance for extensive monitoring period in certain cases, especially in patients taking concurrently AV node blocker agents.
650    _2
$a zvířata $7 D000818
650    _2
$a nodus atrioventricularis $x účinky léků $x patofyziologie $7 D001283
650    _2
$a disekce $7 D004210
650    _2
$a fingolimod hydrochlorid $x farmakologie $7 D000068876
650    _2
$a regulace genové exprese $x účinky léků $7 D005786
650    _2
$a lysofosfolipidy $x farmakologie $7 D008246
650    _2
$a messenger RNA $x genetika $x metabolismus $7 D012333
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a receptory lysosfingolipidů $x metabolismus $7 D049349
650    _2
$a reperfuzní poškození $x patologie $x patofyziologie $7 D015427
650    _2
$a sfingosin $x analogy a deriváty $x farmakologie $7 D013110
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kruzliak, Peter $u Department of Cardiovascular Diseases, International Clinical Research Center, St. Anne's University Hospital and Masaryk University, Brno, Czech Republic.
700    1_
$a Rotrekl, Vladimir $u Department of Cardiovascular Diseases, International Clinical Research Center, St. Anne's University Hospital and Masaryk University, Brno, Czech Republic. Department of Medical Physics and Biophysics, Faculty of Medicine, Pavol Jozef Safarik University, Kosice, Slovak Republic.
700    1_
$a Lei, Ming $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Department of Pharmacology, University of Oxford, Oxford & Institute of Cardiovascular Sciences, UK.
773    0_
$w MED00006785 $t Journal of cellular and molecular medicine $x 1582-4934 $g Roč. 19, č. 7 (2015), s. 1729-34
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25864579 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20160414121454 $b ABA008
999    __
$a ok $b bmc $g 1113776 $s 934715
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 19 $c 7 $d 1729-34 $e 20150413 $i 1582-4934 $m Journal of cellular and molecular medicine $n J Cell Mol Med $x MED00006785
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Možnosti archivace